Optimizing tamoxifen therapy: the importance of pharmacogenetic testing to improve adherence

Tamoxifen is the gold standard of endocrine therapy in patients with ER+ breast cancer. However, the efficacy of tamoxifen directly depends on adherence to treatment. Adherence may decrease due to adverse drug reactions and individual differences in drug metabolism. The article presents data from a study of adherence to tamoxifen therapy after 5 years of follow-up in relation to pharmacogenetic associations and adverse drug reactions. Pharmacogenetic testing can improve adherence to treatment by personalizing therapy and reducing the incidence of adverse drug events.